Abstract
To elucidate the mechanism of action for intratumoral injection of immunopotentiators, infiltrating mononuclear cells and tumor necrosis factor (TNF) were assayed by immunostaining tissue samples of differentiated thyroid cancer resected with or without presurgical local application of OK-432, a streptococcal preparation. Frozen sections of resected specimens were stained with monoclonal antibodies using either a conventional or a modified immunoperoxidase method. The tumors injected with OK-432 showed increased T lymphocyte infiltration and HLA-DR expression on cancer cells as compared to the non-injected controls. Among these T cells, the CD4+ subset was more numerous than the CD8+ population. In four out of the seven cases constituting the injected group, numerous TNF-positive cells were seen in clusters or lines as well as scattered, while none of the seven cases in the control group was associated with a considerable amount of these cells. In their morphology and distribution pattern, these TNF-positive cells appeared to be of macrophage lineage. Thus local injection of OK-432 in thyroid cancer was shown to recruit T lymphocytes of predominantly the CD4+ subset and to induce in situ production of TNF, a known potent tumoricidal cytokine. The present data warrant further studies in this direction besides wider clinical intratumoral application of the reagent.
Key words: T lymphocyte, Tumor necrosis factor, Thyroid cancer
References
- 1.Aggarwal BB, Kohr WJ, Hass PE, Moffat B, Spencer SA, Henzel WJ, Bringman TS, Nedwin GE, Goeddel DV, Harkins RN. Human tumor necrosis factor. J Biol Chem. 1985;260:2345. [PubMed] [Google Scholar]
- 2.Akura Y, Tanaka N, Kobayashi G, Gotoh A, Gouchi A, Kamitani S, Gangi J, Orita K. The effects of intratumoral OK-432 injection in gastric cancer patients. In: Tobe T, editor. New applications of OK-432. Tokyo: Excerpta Medica; 1986. p. 75. [Google Scholar]
- 3.Chensue SW, Remick DG, Shmyr-Forsch C, Beals TF, Kunkel S. Immunohistochemical demonstration of cytoplasmic and membrane-associated tumor necrosis factor in murine macrophages. Am J Pathol. 1988;133:564. [PMC free article] [PubMed] [Google Scholar]
- 4.Hojo H, Hashimoto Y. Cytotoxic cells induced in tumor-bearing rats by a streptococcus preparation (OK-432) Gann. 1981;72:692. [PubMed] [Google Scholar]
- 5.Ichimura O, Suzuki S, Saito M, Sugawara Y, Ishida N. Augmentation of interleukin 1 and interleukin 2 production by OK-432. Int J Immunopharmacol. 1985;7:263. doi: 10.1016/0192-0561(85)90035-9. [DOI] [PubMed] [Google Scholar]
- 6.Kokunai I, Shimano T, Sekimoto K, Takeda T, Kobayashi T, Yayoi E, Yamamoto A, Mori T. Induction of tumor necrosis factor by administration of OK-432 in cancer patients. J Clin Lab Immunol. 1986;21:169. [PubMed] [Google Scholar]
- 7.Kraiem Z, Sobel E, Sadeh O, Kinarty S, Lahat N. Effects of γ-interferon on DR antigen expression, growth, 3,5,3′-triiodothyronine secretion, iodide uptake, and cyclic adenosine 3′,5′-monophosphate accumulation in cultured human thyroid cells. J Clin Endocrinol Metab. 1990;71:817. doi: 10.1210/jcem-71-4-817. [DOI] [PubMed] [Google Scholar]
- 8.Misaki T, Dokoh S. Two cases of differentiated thyroid cancer treated with local injection of OK-432 (in Japanese) Ther Res. 1990;11:3779. [Google Scholar]
- 9.Misaki T, Konishi J, Nakashima T, Iida Y, Kasagi K, Endo K, Uchiyama T, Kuma K, Torizuka K. Immunohistological phenotyping of thyroid infiltrating lymphocytes in Graves' disease and Hashimoto's thyroiditis. Clin Exp Immunol. 1985;60:104. [PMC free article] [PubMed] [Google Scholar]
- 10.Misaki T, Tramontano D, Ingbar SH. Effects of rat γ- and non-γ-interferons on the expression of Ia antigen, growth, and differentiated functions of FRTL5 cells. Endocrinology. 1988;123:2849. doi: 10.1210/endo-123-6-2849. [DOI] [PubMed] [Google Scholar]
- 11.Miwa H, Gohchi A, Moriyasu F, Orita K. Increase in T cell infiltration in carcinoma tissue and regional lymph node reaction to gastric cancer after local injection of immunomodulators before gastrectomy. In: Aoki T, Tsubura E, Urushizaki I, editors. Manipulation of host defence mechanisms. Amsterdam: Excerpta Medica; 1984. p. 13. [Google Scholar]
- 12.Oettgen HF, Old LJ. Tumor necrosis factor. In: Rosenberg SA, Herrman S, DeVita VT Jr, editors. Important advances in oncology. Philadelphia: Lippincott; 1987. p. 105. [PubMed] [Google Scholar]
- 13.Saito M, Ebina T, Koi M, Yamaguchi T, Kawade Y, Ishida N. Induction of interferon-γ in mouse spleen cells by OK-432, a preparation ofStreptococcus pyogenes . Cell Immunol. 1982;68:187. doi: 10.1016/0008-8749(82)90102-2. [DOI] [PubMed] [Google Scholar]
- 14.Saito M, Nanjo M, Aonuma E, Noda T, Nakadate I, Ebina T, Ishida N. Activated macrophages are responsible for the tumor-inhibitory effect in mice receiving intravenous injection of OK-432. Int J Cancer. 1984;33:271. doi: 10.1002/ijc.2910330217. [DOI] [PubMed] [Google Scholar]
- 15.Sawaki S, Tsukuda M, Mitarai K. Clinical evaluation of nonspecific immunotherapy with OK-432 for head and neck cancer. In: Ota K, editor. Clinical application of OK-432 for control of cancer. Tokyo: Excerpta Medica; 1986. p. 255. [Google Scholar]
- 16.Selby P, Hobbs S, Viner C, Jackson E, Jones A, Newell D, Calvert AH, McElwain T, Fearon K, Humphreys J, Shiga T. Tumour necrosis factor in man: clinical and biological observations. Br J Cancer. 1987;56:803. doi: 10.1038/bjc.1987.294. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Stötter H, Wiebke EA, Tomita S, Belldegrun A, Topalian S, Rosenberg SA, Lotze MT. Cytokines alter target cell susceptability to lysis. II. Evaluation of tumor infiltrating lymphocytes. J Immunol. 1989;142:1767. [PubMed] [Google Scholar]
- 18.Sugenoya A, Usuda N, Adachi W, Kaneko G, Nagata T, Iida F. Immunohistochemical studies on local antitumor effects of streptococcal immunopotentiator, OK-432, in human solid malignant tumors. Arch Pathol Lab Med. 1988;112:545. [PubMed] [Google Scholar]
- 19.Umesaki N, Ooshita Y, Kawabata M, Sako H, Sugawa T. Experimental and clinical efficacy of locally administered OK-432, in particular against gynecological cancer. In: Tobe T, editor. New applications of OK-432. Tokyo: Excerpta Medica; 1986. p. 102. [Google Scholar]
- 20.Urban JL, Rothstein JL, Shephard MH, Schreiber H. Tumornecrosis factor: a potent mediator of macrophage-dependant tumorcell killing. Haematol Blood Trans. 1987;31:351. doi: 10.1007/978-3-642-72624-8_73. [DOI] [PubMed] [Google Scholar]
- 21.Watanabe N, Niitsu Y, Yamauchi N, Neda H, Sone H, Urushizaki I, Yamamoto A, Nagamuta M, Sugawara Y. Therapeutic effect of OK-432 induced endogenous TNF on tumor bearing mice and cancer patients. Immunopharmacol Immunotoxicol. 1988;10:53. doi: 10.3109/08923978809014401. [DOI] [PubMed] [Google Scholar]
- 22.Watanabe Y, Yamada T, Hashizume Y, Iwa T. Clinical value of immunotherapy with the streptococcal preparation, OK-432 for lung cancer: a randomized study. In: Ota K, editor. Clinical application of OK-432 for control of cancer. Tokyo: Excerpta Medica; 1986. p. 105. [Google Scholar]
- 23.Yagita A, Watanabe Y, Ito H, Tatekawa I, Saito M, Ishida N. Relationship between HLA antigens and immune response in Su-PS skin tests, and between the H-2 system and blastogenic activity in the presence of OK-432. In: Hoshino T, editor. Immunopharmacological aspects of OK-432 in humans. Tokyo: Excerpta Medica; 1986. p. 225. [Google Scholar]
- 24.Yamamoto A, Nagamuta M, Usami H, Sugawara Y, Watanabe N, Niitsu Y, Urushizaki I. Release of tumor necrosis factor (TNF) into mouse peritoneal fluids by OK-432, a streptococcal preparation. Immunopharmacology. 1986;11:79. doi: 10.1016/0162-3109(86)90027-5. [DOI] [PubMed] [Google Scholar]